What is MBX Biosciences, Inc.'s operating lease liabilities?

MBX Biosciences, Inc. (MBX) reported operating lease liabilities of -$41K in Q1 2026.

How has MBX Biosciences, Inc.'s operating lease liabilities changed year-over-year?

MBX Biosciences, Inc.'s operating lease liabilities increased by 2.4% year-over-year, from -$42K to -$41K.

MBX Biosciences, Inc. MBX Operating lease liabilities

Operating lease liabilities at other companies

Viking TherapeuticsVKTX

——

Amylyx Pharmaceuticals, Inc.AMLX

——

BridgeBio PharmaBBIO

——

Nurix Therapeutics, Inc.NRIX

——

Crinetics PharmaceuticalsCRNX

——

XER

Xeris Biopharma Holdings, Inc.XERS

——

Other financials

Income statement

See full

Operating income-$27.3M-2.8%

Net income-$23.5M+1.5%

EPS (diluted)-$0.50+29.6%

Balance sheet

See full

Cash & equivalents$45.2M+51.2%

Total debt$555.0K+327%

Total equity$437.8M+85.9%

Total assets$452.7M+84.1%

Cash flow

See full

Operating cash flow-$20.2M+10.9%

CapEx$437.0K+1,357%

Free cash flow-$20.6M+9.1%

Valuation

See full

Market cap$2.3B+475%

Returns & leverage

See full

Return on equity-25.7%—

Debt / equity0×0.0×

Current ratio30.8×+7.5×

Where this comes from

Reported directly by MBX Biosciences, Inc. in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInOperatingLeaseLiability.

The official record: MBX Biosciences, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about MBX Biosciences, Inc.'s operating lease liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is MBX Biosciences, Inc.'s operating lease liabilities?: MBX Biosciences, Inc. (MBX) reported operating lease liabilities of -$41K in Q1 2026.
How has MBX Biosciences, Inc.'s operating lease liabilities changed year-over-year?: MBX Biosciences, Inc.'s operating lease liabilities increased by 2.4% year-over-year, from -$42K to -$41K.